Diabetes is one of the most studied diseases in medicine, yet it remains one of the most misunderstood — partly because “diabetes” isn’t really one disease at all. It’s a family of related conditions that share a single feature — elevated blood glucose — but arise from very different underlying mechanisms, progress differently, and increasingly, don’t fit neatly into the categories most people grew up hearing about. Here’s a complete look at what diabetes actually is, how it’s classified, what causes it, how it’s diagnosed and managed worldwide, and where the science is still evolving.
What Diabetes Actually Is
Diabetes mellitus is a group of metabolic disorders in which the body either doesn’t produce enough insulin, doesn’t use insulin effectively, or both. Insulin is the hormone responsible for allowing glucose to move from the bloodstream into cells, where it’s used for energy. When that system breaks down, glucose builds up in the blood, and over years, that chronic excess damages blood vessels and organs throughout the body — which is why diabetes is as much a vascular disease as it is a metabolic one.
The Global Scale of Diabetes
According to the International Diabetes Federation’s 11th edition Diabetes Atlas (2025), an estimated 589 million adults aged 20–79 are living with diabetes worldwide — 11.1% of that age group. That number is projected to climb to roughly 853 million by 2050. Perhaps the most sobering figure: an estimated 252 million people with diabetes don’t yet know they have it.
China and India carry the two largest national disease burdens globally, with India alone accounting for approximately 89 million cases. South and East Asia have emerged as the epicenter of the global diabetes epidemic — not simply due to population size, but because diabetes in this region tends to appear earlier in life, in leaner individuals, and progress differently than the classical Western pattern most diagnostic frameworks were originally built around.
The Types of Diabetes, Explained
Type 1 Diabetes
An autoimmune condition in which the immune system mistakenly destroys insulin-producing beta cells in the pancreas. It typically presents in childhood or young adulthood, though the ADA’s 2025 guidance is explicit that Type 1 diabetes can occur at any age — challenging older assumptions that it’s exclusively a childhood disease. People with Type 1 diabetes require insulin for survival, since their bodies produce little to none of it. The presence of multiple islet autoantibodies is a strong predictor of eventual clinical Type 1 diabetes.
Type 2 Diabetes
The most common form globally, accounting for roughly 90% of all diabetes cases. It develops when the body becomes resistant to insulin’s effects and, over time, the pancreas can no longer produce enough insulin to compensate. It’s strongly associated with excess body weight, physical inactivity, and genetic predisposition, though — as discussed below — the “typical” Type 2 profile looks meaningfully different across populations.
Gestational Diabetes
Diabetes first diagnosed during pregnancy, resulting from hormonal changes that increase insulin resistance. It usually resolves after delivery but significantly raises a woman’s lifetime risk of developing Type 2 diabetes later on, and requires careful management to reduce risks to both mother and baby.
Monogenic Diabetes (MODY and Neonatal Diabetes)
A form of diabetes caused directly by a mutation in a single gene, rather than the complex, multi-gene-and-lifestyle interplay behind Type 1 and Type 2. It includes Maturity-Onset Diabetes of the Young (MODY) and neonatal diabetes (onset before 6 months of age). Over 43 genes have now been linked to monogenic diabetes, and it’s estimated to represent 1–6% of all diabetes cases — a small percentage that, at global case numbers, still adds up to millions of people. It’s also widely documented as underdiagnosed and frequently misclassified as Type 1 or Type 2, because its clinical presentation overlaps with both. This distinction matters clinically: some monogenic subtypes (like GCK-related diabetes) need no medication at all, while others (like HNF1A- or HNF4A-related diabetes) often respond far better to sulfonylurea tablets than to insulin — even in patients previously started on insulin under the wrong label.
Type 5 Diabetes — A Newly Recognized Category (2025)
In January 2025, an international consensus — subsequently endorsed by the IDF World Diabetes Congress — formally recognized a phenotype first described in 1955 but long neglected: Type 5 diabetes. It occurs in lean individuals with a lifelong history of undernutrition, and is marked by severely impaired insulin secretion alongside preserved insulin sensitivity — essentially the inverse metabolic signature of typical Type 2 diabetes. It’s estimated to affect 20–25 million people worldwide, concentrated in low- and middle-income countries, and existing Type 1/Type 2 treatment protocols are considered inadequate for it. This reclassification is a useful reminder that diabetes categories are not fixed textbook fact — they continue to evolve as science catches up with the real diversity of patients.
What Causes Diabetes: Risk Factors by Type
- Type 1: Autoimmune destruction of beta cells, with genetic susceptibility (certain HLA gene variants) and as-yet-incompletely-understood environmental triggers.
- Type 2: A combination of genetic predisposition, excess body weight (particularly visceral fat), physical inactivity, aging, and — increasingly recognized — ethnicity-specific differences in how body fat and insulin resistance interact.
- Gestational: Pregnancy-related hormonal changes, with higher risk in women who are older, overweight, or have a family history of diabetes.
- Monogenic: A single inherited gene mutation, typically following autosomal dominant inheritance (meaning each child of an affected parent has roughly a 50% chance of inheriting it).
- Type 5: Chronic undernutrition during critical developmental periods, thought to impair pancreatic development itself.
ADA risk-assessment guidance for Type 2 diabetes and prediabetes screening in asymptomatic adults highlights a cluster of risk factors: overweight or obesity, a history of cardiovascular disease, hypertension (≥130/80 mmHg), high triglycerides, low HDL cholesterol, polycystic ovary syndrome, physical inactivity, and a family history of diabetes.
Recognizing the Symptoms
Common symptoms across diabetes types include excessive thirst (polydipsia), frequent urination (polyuria), unexplained hunger (polyphagia), unexplained weight loss, blurry vision, and extreme fatigue. Type 1 diabetes often presents more suddenly and dramatically, sometimes with diabetic ketoacidosis as the first sign. Type 2 diabetes frequently develops silently over years, which is a major reason such a large share of cases worldwide remain undiagnosed until complications appear.
How Diabetes Is Diagnosed
International diagnostic criteria, as codified in the ADA’s Standards of Care (updated annually, most recently for 2026), rely on any of the following:
- HbA1c ≥ 6.5% (glycated hemoglobin, reflecting average blood glucose over roughly the prior three months)
- Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
- 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75-gram oral glucose tolerance test (OGTT)
- Random plasma glucose ≥ 200 mg/dL in someone with classic hyperglycemia symptoms
Prediabetes is defined by values that fall short of these thresholds but above normal — an HbA1c of 5.7–6.4%, for instance — and significantly raises future risk of both diabetes and cardiovascular disease. Certain conditions (anemia, hemoglobin variants, pregnancy, kidney dialysis, HIV treatment) can distort A1c results, in which case direct plasma glucose testing is used instead.
The Complications: Why Long-Term Control Matters
Diabetes complications are broadly split into two categories:
Microvascular complications (damage to small blood vessels):
- Retinopathy — damage to blood vessels in the retina, a leading cause of preventable blindness in adults
- Nephropathy — progressive kidney damage that can lead to chronic kidney disease and kidney failure
- Neuropathy — nerve damage, often first noticed as numbness or tingling in the feet, which also raises the risk of foot ulcers and, in severe cases, amputation
Macrovascular complications (damage to larger blood vessels):
- Cardiovascular disease, including heart attack and heart failure
- Cerebrovascular disease, including stroke
- Peripheral arterial disease
Diabetes-related cardiovascular disease remains the leading cause of death among people with diabetes globally. Encouragingly, large randomized trials have consistently shown that intensive, sustained glycemic management can prevent or meaningfully delay the onset and progression of retinopathy specifically, and similar principles apply across other complications — which is the central rationale behind aggressive early treatment.
How Diabetes Is Treated
Management approaches differ meaningfully by type, but the global treatment landscape includes:
- Lifestyle intervention — nutrition changes, physical activity, and weight management remain foundational across nearly all forms of Type 2 diabetes and prediabetes.
- Metformin — typically the first-line oral medication for Type 2 diabetes worldwide, improving insulin sensitivity.
- SGLT2 inhibitors — a newer drug class that lowers blood glucose by promoting glucose excretion through urine, with demonstrated cardiovascular and kidney-protective benefits in Type 2 diabetes.
- GLP-1 receptor agonists (GLP-1 RAs) — one of the most significant recent developments in diabetes treatment, this class (including semaglutide, liraglutide, and dulaglutide) improves glycemic control and has shown notable cardiovascular benefits, including reduced ischemic stroke risk in trial meta-analyses. Retinopathy status is specifically monitored when starting these medications, since rapid A1c reduction has been associated with initial, transient worsening in some patients with existing retinopathy.
- Insulin therapy — essential for all Type 1 diabetes, and used in Type 2 diabetes when other therapies aren’t sufficient to reach glycemic targets.
- Sulfonylureas — often highly effective for specific monogenic diabetes subtypes (HNF1A, HNF4A), sometimes allowing patients to come off insulin entirely once correctly diagnosed.
Ongoing care also includes structured screening: eye exams for retinopathy, kidney function monitoring for nephropathy, foot exams for at-risk patients (especially those with sensory loss, prior ulcers, or long diabetes duration), and cardiovascular risk assessment — all recommended as routine, recurring parts of diabetes management under current international standards of care.
Prevention: What the Evidence Actually Supports
For Type 2 diabetes specifically — the form most amenable to prevention — the strongest evidence supports sustained weight management, regular physical activity, and dietary pattern changes, particularly in people identified as having prediabetes through risk-factor screening. Type 1 diabetes, by contrast, currently has no proven preventive strategy; the ADA’s 2025 standards note there are presently no approved therapies for preserving insulin-producing capacity or delaying progression of symptomatic Type 1 diabetes, though this remains an active area of research.
The Genetics of Diabetes: More Than Just Family History
Genetics plays a role across every type of diabetes, but in very different ways:
- In Type 1 diabetes, specific HLA gene variants influence autoimmune susceptibility, though genetics alone doesn’t fully explain disease onset.
- In Type 2 diabetes, risk is polygenic — influenced by many genes, each contributing a small effect, interacting with lifestyle and environmental factors. This is distinct from single-gene forms and explains why family history alone can’t predict individual risk precisely.
- In monogenic diabetes, a single gene mutation is the direct cause, following clear inheritance patterns and, in many cases, changing what treatment actually works.
Because monogenic diabetes is so frequently misdiagnosed as Type 1 or Type 2, international clinical patterns increasingly flag genetic testing as worth considering when diabetes appears at a young age (particularly under 25–30) without obesity, follows a strong multigenerational family pattern, doesn’t show typical Type 1 autoimmune markers, doesn’t show typical Type 2 insulin-resistance features, or begins in the first six months of life. In these scenarios, genetic testing — ranging from targeted gene panels to broader tools like Whole Exome Sequencing when initial testing is inconclusive — has changed real treatment decisions for patients previously managed under an incorrect diabetes label.
Diabetes in India: A Genuinely Distinct Picture
India’s diabetes burden isn’t simply a larger version of the global pattern — it has well-documented, distinctive features:
- The ICMR-INDIAB study, India’s largest national diabetes survey, found a mean national prevalence of 7.3%, with wide variation by state.
- Nationwide youth screening data found diabetes prevalence of 17.9% among those under 35 with a family history of diabetes, and 9.8% even among those under 25 — strikingly high figures by global comparison.
- Research comparing Asian Indian and European populations found that young-onset diabetes in Asian Indians is associated with measurably lower beta-cell function — both clinically measured and genetically determined — a distinct phenotype from typical Western young-onset Type 2 diabetes.
- South Asians living in high-income countries are consistently diagnosed with diabetes 5 to 10 years earlier than white European populations, even after accounting for established risk factors — a gap current genetic knowledge only partially explains.
- Fewer than one in four people with diabetes on regular treatment in India have achieved recommended glycemic control (HbA1c <7%), according to the largest national epidemiological study conducted.
In short: young-onset, lean-phenotype, or strongly family-history-positive diabetes isn’t a rare edge case in India — it’s a well-documented pattern in the country’s own national data.
Where the Science Still Isn’t Settled
- Type 5 diabetes is newly classified, and its full clinical and genetic boundaries are still being actively defined by the international research community.
- The genetic basis of the South Asian early-onset diabetes phenotype remains incompletely explained — measurable beta-cell differences exist, but currently known genetic variants don’t fully account for the age-of-onset gap.
- No approved therapy currently exists to prevent or delay Type 1 diabetes progression, despite substantial ongoing research investment.
- Diagnostic yield gaps persist even with genetic testing — a meaningful share of patients with strong clinical suspicion of monogenic diabetes still test negative on current panels, suggesting undiscovered genetic causes remain to be found.
- GLP-1 receptor agonists’ long-term retinopathy effects beyond the initial treatment period aren’t yet fully characterized in trials specifically designed to study that risk.
The Bottom Line
Diabetes is not one disease — it’s a spectrum of related conditions, and that picture keeps getting more precise as research continues, most recently with the 2025 recognition of Type 5 diabetes. For the overwhelming majority of people, standard diagnostic pathways and treatment approaches work well. But for those whose diabetes doesn’t quite fit the expected pattern — early onset, a lean build, a strong family history, or an unexpected treatment response — understanding that a distinct, sometimes genetic, explanation may exist is often the first step toward more accurate, more personalized care. For cases where standard evaluation hasn’t provided a clear answer, comprehensive genetic testing such as Whole Exome Sequencing is one of the tools available to help identify an underlying genetic cause.
Frequently Asked Questions
1. What are the different types of diabetes?
Diabetes is broadly classified into several types. Type 1 diabetes is an autoimmune condition where the immune system destroys insulin-producing cells. Type 2 diabetes is the most common form, characterized by insulin resistance and relative insulin deficiency. Gestational diabetes develops during pregnancy. Monogenic diabetes (including MODY and neonatal diabetes) is caused by a single gene mutation. Type 5 diabetes is a newly recognized form occurring in lean individuals with a history of undernutrition.
2. What is monogenic diabetes and how is it different from Type 1 and Type 2?
Monogenic diabetes is caused by a mutation in a single gene, unlike Type 1 (autoimmune) and Type 2 (polygenic with lifestyle factors). It typically presents before age 25, follows an autosomal dominant inheritance pattern (50% chance of passing to children), and is not associated with obesity or autoimmune markers. Over 43 genes have been linked to monogenic diabetes, with GCK and HNF1A being the most common.
3. Why is genetic testing important for diabetes diagnosis?
Genetic testing is crucial because an estimated 1–6% of diabetes cases are monogenic but are frequently misdiagnosed as Type 1 or Type 2. Correct genetic diagnosis can change treatment—for example, patients with HNF1A mutations often respond better to sulfonylurea tablets than insulin, while those with GCK mutations may need no medication at all. This prevents years of unnecessary or suboptimal treatment.
4. Who should consider genetic testing for diabetes?
Genetic testing should be considered if diabetes is diagnosed at a young age (typically under 25–30 years), in the absence of obesity, with a strong multigenerational family history, without typical Type 1 autoimmune markers, or if it begins in the first six months of life. These features suggest a possible monogenic cause rather than the more common Type 1 or Type 2 forms.
5. What is Whole Exome Sequencing (WES) and how does it help in diabetes diagnosis?
Whole Exome Sequencing (WES) is a comprehensive genetic test that analyzes all protein-coding regions of the genome—approximately 23,000 genes. Unlike targeted gene panels that examine a limited set of genes, WES provides a more complete molecular picture. It can identify the precise gene mutation causing monogenic diabetes, enabling accurate diagnosis and personalized treatment. It may also uncover secondary findings with significant health implications.
6. What are the symptoms of diabetes?
Common symptoms include excessive thirst (polydipsia), frequent urination (polyuria), unexplained hunger (polyphagia), unexplained weight loss, blurry vision, and extreme fatigue. Type 1 diabetes often presents more suddenly and dramatically, sometimes with diabetic ketoacidosis as the first sign. Type 2 diabetes frequently develops silently over years, which is why many cases remain undiagnosed until complications appear.
